Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nedocromil is a small molecule anti-inflammatory agent classified as a mast cell stabilizer. It is used to prevent symptoms of asthma and allergic conjunctivitis. Inhaled nedocromil reduces the number and severity of asthma attacks by inhibiting the activation and degranulation of inflammatory cells such as mast cells, eosinophils, neutrophils, macrophages, monocytes, and platelets in the lungs. This prevents the release of mediators like histamine, leukotrienes, prostaglandins, and tryptase that contribute to airway inflammation and bronchospasm[1][2][5][7][9]. Ophthalmic formulations are used for allergic conjunctivitis by preventing mast cell degranulation in ocular tissues[3][10]. The drug does not provide relief for acute asthma or allergy attacks but is effective when used regularly as prophylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nedocromil.